Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RemeGen Co. Ltd. Class H ( (HK:9995) ) has issued an update.
RemeGen Co., Ltd. has announced a discloseable transaction involving the purchase of wealth management products from SPDB Yantai Branch, utilizing idle self-owned funds and raised proceeds. The transaction involves a total investment of RMB500 million, with the aim of optimizing cash management and potentially enhancing financial returns through principal-guaranteed products linked to the EUR-USD exchange rate. This move is subject to reporting and announcement requirements under the Hong Kong Listing Rules, reflecting the company’s strategic financial management efforts.
The most recent analyst rating on (HK:9995) stock is a Sell with a HK$89.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on developing innovative drugs and therapies, particularly in the field of biotechnology, to address unmet medical needs.
Average Trading Volume: 7,968,326
Technical Sentiment Signal: Buy
Current Market Cap: HK$55.1B
For a thorough assessment of 9995 stock, go to TipRanks’ Stock Analysis page.